Startseite>>Signaling Pathways>> PROTAC>> Ligand for E3 Ligase>>Lenalidomide-OH

Lenalidomide-OH

Katalog-Nr.GC60223

Lenalidomid-OH ist ein Analogon des Cereblon (CRBN)-Liganden Lenalidomid fÜr die E3-Ubiquitin-Ligase und wird zur Rekrutierung des CRBN-Proteins verwendet. Lenalidomid-OH kann mit dem Liganden fÜr Protein durch einen Linker verbunden werden, um PROTACs zu bilden, wie z. B. den PROTAC BTK-Abbauer SJF620.

Products are for research use only. Not for human use. We do not sell to patients.

Lenalidomide-OH Chemische Struktur

Cas No.: 1416990-08-3

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
134,00 $
Auf Lager
10mM (in 1mL DMSO)
114,00 $
Auf Lager
100mg
122,00 $
Auf Lager
500mg
365,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BTK degrader SJF620 [1].

Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins[1].

[1]. Jaime-Figueroa S, et al. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. 2020 Feb 1;30(3):126877.

Bewertungen

Review for Lenalidomide-OH

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Lenalidomide-OH

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.